Study Design and Study Population
This split-face, evaluator-blinded, randomized control trial studied whether multiple subcision treatments would improve the appearance of rolling acne scars. The study took place from October 2014 to July 2016. A total of 5 patients who met inclusion and exclusion criteria were enrolled in the study and 4 patients completed the study per protocol. Inclusion criteria for subjects included being 18 to 65 years old, having bilateral rolling acne scars on each side of their face, being in good health, and having the willingness and the ability to understand and provide informed consent for the use of their tissue and communicate with the investigator. Exclusion criteria included being under 18 years of age, being pregnant or lactating, being unable to understand the protocol or to give informed consent, having mental illness, recent Accutane use in the past 6 months, being prone to hypertrophic and keloidal scarring, subject reports of any blood diseases (HIV, Hepatitis, etc), and subject reports of history of Herpes (oral or genital).
Participants underwent five sequential subcision treatments, each spaced four weeks apart. One side of the face was randomized to receive multiple subcision treatments, while the contralateral side received no treatment.
Digital photographs were taken in standard front and lateral views before the subcision and immediately after the procedure on the initial visit. Sociodemographic information, including age, race, gender, ethnicity, and Fitzpatrick phototype, for each subject was collected on the initial visit. The Fitzpatrick phototype was collected as part of the sociodemographics information to provide objective data for skin color. The Fitzpatrick Scale is a standardized 6-point scale describing the pigmentation of skin, with lighter skin types comprising Fitzpatrick phototypes I-IV, brown pigmented skin comprising Fitzpatrick phototype V, and black pigmented skin comprising Fitzpatrick phototype VI.12
Additional photographs were taken at Weeks 4, 8, 12, 16, 20, and 36 from the initial visit. Standard assessments in acne scar appearance were made by the subject and one live blinded investigator at baseline. Assessments were also made by these individuals at Weeks 4, 8, 12, 16, 20, and 36 (compared to baseline). In addition, two double-blinded investigators made assessments utilizing photographs at Weeks 4, 8, 12, 16, 20, and 36 (compared to baseline).
Before subcision, the scar site was cleansed with chlorhexidine antibacterial solution and marked with a water-soluble marker. Subcutaneous anesthetic (1% lidocaine with epinephrine 1:100,000) was administered via a 30-gauge needle. At the start of the procedure, a Sharpoint ®"The Surgeon's Edge" 20 gauge Microsurgical (1.4 mm), straight vitrectomy knife (Ref 71-2001)13 was inserted subdermally and slowly advanced parallel to the dermis. Rapid advancement and retraction of the needle under the scarred area in a lancing motion were performed to abrade the underside of the dermis, followed by side to side sweeping motions attempting to break any fibrous attachments to the deeper tissues. The subcised area was covered with Vaseline and a light gauze dressing. Treatments two through five were administered in the same manner as the initial procedures on weeks 4, 8, 12, and 16 after the initial visit.
Subjects returned for follow-up visits 20 weeks and 36 weeks after Day 1. Front and lateral view photographs were taken at these visits. Subjects were asked to rate which side they were more content with in terms of overall scar improvement. They were also asked to evaluate their scars using a percent improvement scale. Live ratings were performed by a blinded rater comparing the right and left sides of the face.
Primary Outcome Measures
Outcomes of the procedures were assessed by the subject, one blinded live rater, and two double-blinded photograph raters. The blinded live rater rated the right and left sides of the face in terms of overall appearance on a percentage scale and calculated global scarring scores per the modified quantitative global scarring grading system (Table 1). In addition, two double-blinded dermatologist raters were asked to examine photographs of the subjects comparing the photographs at Weeks 4, 8, 12, 16, 20, and 36 to those of baseline, using the same evaluations as above. The subjects were asked to complete a scar survey assessment scale to evaluate their scars at 20 and 36 weeks from Day 1.
Table 1
Modified Quantitative Global Scarring Grading System
(Grade) Type | Number of lesions on left side of face: | Number of lesions on right side of face |
(A) Milder scarring | | |
• Macular erythematous or pigmented | | |
• Mildly atrophic dish-like | | |
(B) Moderate scarring | | |
• Moderately atrophic dish-like | | |
• Punched out with shallow bases small scars (< 5 mm) | | |
• Shallow but broad atrophic areas | | |
(C) Severe scarring | | |
• Punched out with deep but normal bases, small scars (< 5 mm) | | |
• Punched out with deep abnormal bases, small scars (< 5 mm) | | |
• Linear or troughed dermal scarring | | |
• Deep, broad atrophic areas | | |
The primary outcome measure was the change in blinded rater assessment of acne scar appearance score on a 5-point scale (0 = no acne scarring; 1 = trace acne scarring, 2 = mild, 3 = moderate, 4 = severe) at Day 1, 20 weeks, and 36 weeks compared to baseline.
Secondary Outcome Measures
Any induration, edema, and bruising were noted at Day 1, Weeks 4, 8, 12, 16, 20, and 36. The occurrence and extent of any adverse events (AE) during the entire duration of the study were noted as well. This included if the subject contacted the investigators on days that were not visit days.
Statistical Methods
Assuming a standard deviation of 1.1, a sample size of 19 patients gives 80% power to detect a 1-unit difference in mean acne scarring between treatments. This calculation assumes α = 0.05 and a two-sided test. As the sample size was below 19 patients, analysis of the 5-point acne scar appearance scores using the Wilcoxon Signed-Rank test and analysis of the scores of the percent improvement scale and the Quantitative Global Scarring Grading System using paired t-tests were not performed. Descriptive statistics evaluating the mean and standard deviation were performed for these outcomes to compare the treatment and control sides.